



Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (cancel)

Claim 2. (cancel)

Claim 3. (cancel)

Claim 4. (previously presented) A method of treating a person having a keratoconjunctival disorder comprising administering an effective amount of a natriuretic peptide to at least one eye of said person.

Claim 5. (currently amended) The method of claim [[3]] 4 wherein said keratoconjunctival disorder is dry eye.

Claim 6. (currently amended) The method of claim [[3]] 4 wherein said keratoconjunctival disorder is corneal erosion.

Claim 7. (currently amended) The method of claim [[3]] 4 wherein said keratoconjunctival disorder is a corneal ulcer.

Claim 8. (previously presented) The method of claim 4 wherein said natriuretic peptide is an atrial natriuretic peptide.

Claim 9. (previously presented) The method of claim 4 wherein said natriuretic peptide is a brain natriuretic peptide.

Claim 10. (previously presented) The method of claim 4 wherein said natriuretic peptide is a C-type natriuretic peptide.

Claim 11. (previously presented) The method of claim 4 wherein the natriuretic peptide is administered as eyedrops in a concentration of 0.001 to 1% (W/V).

Claim 12. (previously presented) The method of claim 4 wherein the natriuretic peptide is administered as eyedrops in a concentration of 0.005 to 0.5% (W/V).

Claim 13. (previously presented) The method of claim 4 wherein the natriuretic peptide is administered as eyedrops in a concentration of 0.05 to 0.5% (W/V).